MedTrace Logo

A Study of SGB-7342 in Subjects With Obesity or Overweight

NCT07324850 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-01-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.

Conditions

  • Obesity & Overweight

Interventions

DRUG

SGB-7342

SC injection, single dose

DRUG

SGB-7342-Matching placebo

Normal saline (0.9% NaCl) in a matching volume, SC injection, single dose

Sponsors & Collaborators

  • Suzhou Sanegene Bio Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-12
Primary Completion
2026-10-28
Completion
2027-04-14

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07324850 on ClinicalTrials.gov